Evidence map›Paper›PMID 37386249›Full record

ArticleNature genetics2023

Single-cell multi-omics of mitochondrial DNA disorders reveals dynamics of purifying selection across human immune cells.

Caleb A Lareau, Sonia M Dubois, Frank A Buquicchio, Yu-Hsin Hsieh, Kopal Garg, Pauline Kautz, Lena Nitsch, Samantha D Praktiknjo, Patrick Maschmeyer, Jeffrey M Verboon and 20 more

Open access · greenAbstract read
In one paragraph

Article in Nature genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Mitochondrial metabolism and cancer therapeutic innovation.Signal transduction and targeted therapy · 2025
    Review
  18. Article
  19. Cell type-specific purifying selection of synonymous mitochondrial DNA variation.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors at 10 institutions in 3 countries.

Caleb A LareauDepartment of Pathology, Stanford University, Stanford, CA, USA. clareau@stanford.edu.ORCID 0000-0003-4179-4807
Sonia M Dubois *Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-3169-2893
Frank A Buquicchio *Department of Pathology, Stanford University, Stanford, CA, USA.
Yu-Hsin Hsieh *Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Institute for Medical Systems Biology (BIMSB), Berlin, Germany.
Kopal GargBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Pauline KautzMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Institute for Medical Systems Biology (BIMSB), Berlin, Germany.ORCID 0000-0002-9658-1676
Lena NitschMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Institute for Medical Systems Biology (BIMSB), Berlin, Germany.
Samantha D PraktiknjoMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Institute for Medical Systems Biology (BIMSB), Berlin, Germany.ORCID 0000-0002-0186-5271
Patrick MaschmeyerMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Institute for Medical Systems Biology (BIMSB), Berlin, Germany.
Jeffrey M VerboonBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Jacob C GutierrezDepartment of Pathology, Stanford University, Stanford, CA, USA.
Yajie YinDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-2220-005X
Evgenij FiskinBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Wendy LuoBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Eleni P MimitouTechnology Innovation Lab, New York Genome Center, New York City, NY, USA.ORCID 0000-0001-9737-6394
Christoph MuusBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Rhea MalhotraBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Sumit ParikhCenter for Pediatric Neurosciences, Mitochondrial Medicine, Cleveland Clinic, Cleveland, OH, USA.
Mark D FlemingDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0948-4024
Lena OevermannDepartment of Pediatric Oncology, Charité-Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany.
Johannes SchulteDepartment of Pediatric Oncology, Charité-Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany.ORCID 0000-0003-0671-1201
Cornelia EckertDepartment of Pediatric Oncology, Charité-Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany.
Anshul KundajeDepartment of Genetics, Stanford University, Stanford, CA, USA.ORCID 0000-0003-3084-2287
Peter SmibertTechnology Innovation Lab, New York Genome Center, New York City, NY, USA.ORCID 0000-0003-0772-1647
Santosha A VardhanaMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-3100-1298
Ansuman T SatpathyDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-5167-537X
Aviv RegevBroad Institute of MIT and Harvard, Cambridge, MA, USA. aviv.regev.sc@gmail.com.ORCID 0000-0003-3293-3158
Vijay G SankaranBroad Institute of MIT and Harvard, Cambridge, MA, USA. sankaran@broadinstitute.org.ORCID 0000-0003-0044-443X
Suneet AgarwalDivision of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. suneet.agarwal@childrens.harvard.edu.ORCID 0000-0003-4910-3118
Leif S LudwigBroad Institute of MIT and Harvard, Cambridge, MA, USA. leif.ludwig@bih-charite.de.ORCID 0000-0002-2916-2164
Broad Institute · USMax Delbrück Center · DEStanford University · USBoston Children's Hospital · USCharité - Universitätsmedizin Berlin · DE10X Genomics (United States) · USCleveland Clinic · USImmunai (United States) · USMemorial Sloan Kettering Cancer Center · USParker Institute for Cancer Immunotherapy · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
The North American Mitochondrial Disease Consortium (NAMDC)U54NS078059 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI VAN HOVE, JOHAN L · 2011 to 2023
$17.5M
Single-cell Mapping Center for Human Regulatory Elements and Gene ActivityUM1HG012076 · NHGRI · STANFORD UNIVERSITY · PI Michael Ryan Corces, Ansuman Satpathy · 2021 to 2026
$13.8M
Systems Biology of Bone Marrow Failure and MDS for Precision MedicineRC2DK122533 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI FIGUEROA, MARIA EUGENIA, FLEMING, MARK D · 2019 to 2023
$6.4M
Systematic Genetic Dissection of Human ErythropoiesisR01DK103794 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI Vijay Ganesh Sankaran · 2014 to 2026
$5.9M
Regulation of the telomerase RNA component in hematopoiesisR01DK107716 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI SUNEET AGARWAL · 2016 to 2026
$5.0M
Identifying Genome-wide Association Study-Nominated Regulators of ErythropoiesisR33HL120791 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI SANKARAN, VIJAY GANESH · 2016 to 2018
$1.7M
Novel small molecules to treat degenerative lung and blood diseasesR33HL154133 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI AGARWAL, SUNEET · 2020 to 2021
$1.2M
Charting somatic evolution via single-cell multiomicsR00HG012579 · NHGRI · SLOAN-KETTERING INST CAN RESEARCH · PI LAREAU, CALEB ANDREW · 2023 to 2025
$747k
Charting somatic evolution via single-cell multiomicsK99HG012579 · NHGRI · STANFORD UNIVERSITY · PI LAREAU, CALEB ANDREW · 2022 to 2022
$119k
Howard Hughes Medical InstituteNCI NIH HHS P30 CA008748NHGRI NIH HHS K99 HG012579NHGRI NIH HHS R00 HG012579NHGRI NIH HHS UM1 HG012076NHLBI NIH HHS R33 HL120791NHLBI NIH HHS R33 HL154133NIDDK NIH HHS R01 DK103794NIDDK NIH HHS R01 DK107716NIDDK NIH HHS RC2 DK122533NINDS NIH HHS U54 NS078059
6 · The paper itself

Abstract

Pathogenic mutations in mitochondrial DNA (mtDNA) compromise cellular metabolism, contributing to cellular heterogeneity and disease. Diverse mutations are associated with diverse clinical phenotypes, suggesting distinct organ- and cell-type-specific metabolic vulnerabilities. Here we establish a multi-omics approach to quantify deletions in mtDNA alongside cell state features in single cells derived from six patients across the phenotypic spectrum of single large-scale mtDNA deletions (SLSMDs). By profiling 206,663 cells, we reveal the dynamics of pathogenic mtDNA deletion heteroplasmy consistent with purifying selection and distinct metabolic vulnerabilities across T-cell states in vivo and validate these observations in vitro. By extending analyses to hematopoietic and erythroid progenitors, we reveal mtDNA dynamics and cell-type-specific gene regulatory adaptations, demonstrating the context-dependence of perturbing mitochondrial genomic integrity. Collectively, we report pathogenic mtDNA heteroplasmy dynamics of individual blood and immune cells across lineages, demonstrating the power of single-cell multi-omics for revealing fundamental properties of mitochondrial genetics.

Indexed as

DNA, MitochondrialMitochondrial DiseasesHumansMitochondriaMultiomicsMutationDNA, Mitochondrial

Identifiers

PMID37386249
PMCPMC10548551
OpenAlexW4382537165

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.